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http://dx.doi.org/10.1016/j.ccr.2013.07.008SUMMARYBasal-like triple-negative breast cancers (TNBCs) have poor prognosis. To identify basal-like TNBC depen-
dencies, a genome-wide siRNA lethality screen compared two human breast epithelial cell lines transformed
with the same genes: basal-like BPLER andmyoepithelial HMLER. Expression of the screen’s 154 BPLER de-
pendency genes correlated with poor prognosis in breast, but not lung or colon, cancer. Proteasome genes
were overrepresented hits. Basal-like TNBC lines were selectively sensitive to proteasome inhibitor drugs
relative to normal epithelial, luminal, and mesenchymal TNBC lines. Proteasome inhibition reduced growth
of established basal-like TNBC tumors in mice and blocked tumor-initiating cell function andmacrometasta-
sis. Proteasome addiction in basal-like TNBCs was mediated by NOXA and linked to MCL-1 dependence.INTRODUCTION
Triple-negative breast cancers (TNBCs), defined by their lack of
estrogen (ER), progesterone (PR), and Her2 receptors, are an
especially aggressive group of tumors that typically afflict
younger women and have the worst prognosis of any breast tu-
mor subtype (Foulkes et al., 2010; Gusterson, 2009). Although
most TNBCs respond to cytotoxic platinum/taxane-containing
regimens, they are prone to recur, metastasize, and become
resistant to chemotherapy (Foulkes et al., 2010; Metzger-Filho
et al., 2012). TNBCs are the breast cancer subtype most
enriched for poorly differentiated CD44+CD24low/ESA+ tumor-
initiating cells (T-ICs), sometimes called cancer stem cells, cellsSignificance
There is no targeted therapy for TNBCs, which are prone to
genome-wide screen identified without bias genetic dependen
a common subtype. The screen led to experiments that showe
subtypes, are commonly addicted to the proteasome and M
tumor-initiating cells (T-ICs) within basal-like cancers did no
T-ICs is a priority of cancer drug development. Although borte
that next-generation proteasome inhibitors are worth investig
182 Cancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc.thought to be responsible not just for tumor initiation but also for
metastasis and resistance to chemotherapy (Al-Hajj et al., 2003).
Because of its poor prognosis, a better understanding of TNBC
and how to treat it is needed.
TNBCs are exceedingly heterogeneous by exome and
genome sequencing (Banerji et al., 2012; Curtis et al., 2012;
Shah et al., 2012; Stephens et al., 2012). Some TNBCs arise in
patients bearing mutations in BRCA1 or BRCA2. Although muta-
tions in TP53 (in 63%–80% of basal TNBC), PIK3CA (in 10% of
TNBC), and PTEN or RB1 (in 8% of TNBC) are common, they
are also found in less-aggressive breast cancers. Moreover,
most mutations occur at <1% frequency in TNBCs, suggesting
that these tumors might be driven by many differentrelapse and metastasize after cytotoxic drug treatment. A
cies, and hence potential drug targets, of basal-like TNBCs,
d that basal-like breast cancers, but not other breast cancer
CL-1 and sensitive to proteasome inhibitors. Importantly,
t survive proteasome inhibition. Developing ways to target
zomib does not penetrate tumors well, our findings suggest
ating for treatment of this TNBC subtype.
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siRNA Screen of Basal-like TNBCsmechanisms. Gene expression by TNBCs is also quite varied. A
recent study based on unsupervised hierarchical clustering of
publicly available gene expression arrays of hundreds of primary
TNBCs suggests that TNBCs can be classified based on their
gene expression into at least seven distinct subtypes (Lehmann
et al., 2011). Nonetheless, the majority of TNBCs typically have
an epithelial progenitor (basal-like) phenotype.
Mammalian RNA interference (RNAi) screens have been a
powerful tool to identify without bias the genetic basis for can-
cer-related processes, including cell proliferation, migration,
and apoptosis, but no studies have harnessed the power of
genome-wide RNAi screening to pinpoint potential vulnerabil-
ities of TNBCs (Luo et al., 2009; Zender et al., 2008).We therefore
performed a genome-wide small interfering RNA (siRNA) lethality
screen to identify selective vulnerabilities associated with a
basal-like phenotype.
RESULTS
BPLERDisplay a Basal-like Phenotype and Are Enriched
for Tumor-Initiating Cells
When normal human breast primary epithelial cells are grown in
chemically defined WIT and MEGMmedia, they expand into two
types of cells, epithelial progenitor cells (BPEC) and myoepithe-
lial cells (HMEC), respectively (Figure 1A) (Ince et al., 2007). After
transformation with TERT, SV40 early region, and HRASV12 in
these media, they give rise to BPLER and HMLER cancer lines.
Despite their shared genetic background and similar rates of
proliferation, BPLER had high tumor-initiating potential, forming
tumors in nude mice with as few as 50 cells, whereas 5 3 104
HMLER did not form tumors in 8 weeks (Figures 1B and 1C).
Switching HMLER to WIT for 2 weeks after transformation did
not affect their rate of proliferation or tumor-initiating potential
(data not shown). Thus, to eliminate possible confounding
effects due to differences in medium, in all subsequent experi-
ments BPLER and HMLERwere both grown inWIT. Both BPLER
and HMLER lacked ESR1, PGR, and ERBB2 expression and
expressed basal markers KRT5, KRT14, KRT17, and EGFR
(Figures S1A and S1B available online). Moreover, they both
displayed the breast T-IC phenotype (CD44+CD24low/ESA+),
suggesting that these markers fall short of specifying tumor-
initiating potential (Figures S1C and S1D). However, BPLER
expressed intermediate levels of both E-cadherin and vimentin
messenger RNA (mRNA) (Figures 1D and 1E) and stained for
both basal CK14 and luminal CK18 proteins (Figure 1F), consis-
tent with an epithelial progenitor phenotype, whereas HMLER
expressed 20-fold more vimentin and negligible amounts of
E-cadherin and only stained for CK14 protein, consistent with
a myoepithelial phenotype.
After orthotopic transplantation in the mammary fat pad of
immunocompromised mice, BPLER initiated tumors that were
histologically similar to human primary TNBC, because they
were poorly differentiated epithelial lesions with focal areas of
glandular differentiation, stained for both CK5 and CK14, and
had high mitotic index, inflammatory infiltrates, reactive stroma,
and pushing borders (Figures S1E and S1F). By principal compo-
nent analysis, the global transcriptional profile of six BPLER
tumors from NOD/SCID mice clustered near human primary
basal-like breast tumors in both the UNC337 (Prat et al., 2010)and Richardson-06 (Richardson et al., 2006) data sets (Figures
1G and S1G).
A Genome-wide siRNA Screen Identifies 154 BPLER
Dependency Genes
Because they were transformed with the same oncogenes,
BPLER and HMLER provide an opportunity to compare selective
vulnerabilities of a basal-like breast epithelial cell line enriched
for T-IC with a closely related myoepithelial cell line with poor
tumor-forming ability. To identify functional dependencies
without bias, we performed a high-throughput genome-wide
siRNA lethality screen in 384-well format by transfecting BPLER
and HMLER cells from the same donor in triplicate wells, each
with a pool of four siRNAs targeting a single gene using the Dhar-
macon siGenome library of 17,378 gene targets. Three days
later, CellTiter-Glo was used to count surviving cells. The
screening conditions were optimized to achieve uniform trans-
fection and sensitivity to knockdown of PLK1, a gene required
for mitosis, and lack of sensitivity to a nontargeting control siRNA
for both cell lines (Figure 2A). Data describing the optimization of
the screen are in Figure S2. Most pools scored within one
median absolute deviation of the plate median (Figure 2B). The
ratio (R) of viable BPLER to viable HMLER cells was calculated.
Of 1,025 siRNA pools that significantly decreased BPLER
viability, 780 affected HMLER similarly. Of the remaining 245
pools, 26 were highly selectively lethal for BPLER (R % 0.55),
76 were moderately selective (0.55 < R % 0.65), and 143 were
modestly selective (0.65 < R % 0.75). To validate these candi-
date hits, we transfected BPLER and HMLER cells separately
with each of the four individual siRNAs comprising each pool.
Among the primary screening hits, 154 reconfirmed with at least
one siRNA (Figure 2C), which we defined as BPLER dependency
genes. Not surprisingly, the validation rates were higher for hits
with lower R values (88% of highly selective, 75% of moderately
selective, and 52% of modestly selective hits). The validated hits
comprise a gene signature of BPLER-selective dependencies.
The 23 highly selective confirmed hits are shown in Figure 2D,
and all hits and data from the screen are provided in Figure 3
and Tables S1 and S2. Sixty-five of the BPLER dependency
genes confirmed with at least two individual siRNAs.
BPLER Dependency Genes Cluster within Defined
Functional Categories
Of the 23 validated highly selective BPLER dependency genes
(Figure 2D), seven are proteasome components (hypergeometric
p value for enrichment 1.13 1014). Three other genes, the spli-
ceosome component PRPF8 and two RNA helicases (DDX19B
andDHX8), are involved inmRNAbiogenesis and nuclear export.
The list also contains four Zinc-finger genes (likely transcriptional
activators), a nuclear receptor coactivator gene SNW1, the cat-
alytic subunit of the PP2A phosphatase PP2CA, and three genes
RAN, RACGAP1, and HAUS3 that regulate the mitotic spindle.
To make sense of the 154 dependency genes, we first group-
ed the hits into well-defined functional categories, using a com-
bination of the Reactome (Croft et al., 2011), KEGG (Kanehisa
et al., 2010), and Wikipathway (Pico et al., 2008) databases (Ta-
bles S3 and S4). Of the 154 genes, 121 hadwell-described anno-
tations that could be grouped into 13 functions with at least three
assigned genes. The proteasome was highly overrepresentedCancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc. 183
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Figure 1. BPLER Has a Basal-like Phenotype and Is Enriched for Tumor-Initiating Cells, Compared to HMLER
(A) Schematic depicting the method used to generate BPLER and HMLER from normal breast epithelial cells. Breast organoids maintained in chemically defined
media (WIT and MEGM) were sequentially transformed with retroviral vectors encoding TERT, SV40 early region, and HRASV12.
(B) CellTiter-Glo assay showing proliferation of BPLER, HMLER, and BPE cells in WIT medium.
(C) Tumor incidence in Nu/J mice 8 weeks after subcutaneous injection of the indicated numbers of BPLER, HMLER, or MCF7 cells.
(D and E) qRT-PCR quantification of E-cadherin (D) and vimentin (E) mRNA in BPLER and HMLER cells.
(F) Immunofluorescence staining of cytokeratins CK14 and CK18 in BPLER and HMLER cells. Images are representative of three independent experiments.
Luminal MCF7 and mesenchymal MB231 cells in (D) and (F) were used as control.
(G) Principal component analysis of mRNA expression profiles of six BPLER tumors, generated in NOD/scid mice, and 337 human primary breast tumors
classified as luminal A, luminal B, normal-like, HER2+, basal-like, and claudin-low in the UNC337 set of primary breast cancers. The two first components are
plotted with the proportion of variance explained by each component contained in the axis labels. Data in (B), (D), and (E) indicate mean ± SD.
See also Figure S1.
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siRNA Screen of Basal-like TNBCswith ten proteasome subunits (p < 33 1010) and six other ubiq-
uitin proteasome system (UPS) genes. Of these, five genes are
involved in ubiquitylation, including two components of the
anaphase-promoting complex (ANAPC2 and ANAPC4) and
one gene NEDD8 that neddylates the cullins to promote mitosis.
We next used GeneMANIA (Warde-Farley et al., 2010) to build a
gene interaction network, incorporating physical and predicted
interactions, colocalization, shared pathways, and shared pro-
tein domains (Figure 3). Eighty-seven genes formed a single in-
teracting network. Genes that participate in the major functional
categories, but are not annotated to have direct protein interac-184 Cancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc.tions, were added to this network to produce a core functional-
interaction module. The proteasome and its associated proteins
constituted a core module, linking multiple dependency genes.
Other broad processes that stood out were metabolism,
including two glycolytic enzyme genes (GAPDH and PFKL), the
G1/S transition, and mitosis. Multiple genes involved in mRNA
expression, including RNA polymerases, DNA binding proteins
(likely transcriptional regulators), and mRNA splicing genes,
were also hits. Most modules, and all ten proteasome subunit
genes, were in the network formed with hits reconfirming with
at least two siRNAs (Figure S3).
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Figure 2. Identification of BPLER-Selective Dependencies by High-Throughput siRNA Screening
(A) Cell viability in BPLER and HMLER transfected in high-throughput screening conditions with a custom-made siRNA library containing nontargeting siRNAs
(192 wells/plate) or si-PLK1 (192 wells/plate). Each dot represents the relative CellTiter-Glo signal from individual wells at a given coordinate in three separate
microplates. The Z’ factor, a measure of screening reproducibility, was calculated (Zhang et al., 1999). For both cell lines, Z’ was >0.7 in each of six microplates
transfected in two separate experiments. No significant edge effect was detected in any experiment.
(B) Distribution of R (ratio of viability of BPLER versus HMLER) and BPLER median absolute deviation (MAD)-based Z score for all 17,378 genes in the siRNA
primary screen library. The Z score measures the deviation of BPLER viability from the plate median. A Z score outside the range of1 to +1 is significant. Genes
were considered hits if R < 0.75 and the BPLER Z score was < 1.5. Colors indicate the relative selectivity of BPLER versus HMLER lethality (green, modestly
selective; blue, moderately selective; red, highly selective).
(C)Numbers of hits in theprimary screen and theconfirmedhits in the secondary screen forwhichat least one individual siRNA from the library pool scoredpositive.
(D) Confirmed highly selective BPLER dependency genes. Hits involved in specific functions are shown in different colors.
See also Figure S2 and Tables S1 and S2.
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Figure 3. BPLER Dependency Genes Cluster within Defined Functional Categories
Functional interaction network of BPLER dependency genes. Genes were grouped according to their participation in the indicated processes. The network was
constructed using Cytoscape. The most highly selective hits are colored red.
See also Figure S3 and Tables S3 and S4.
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siRNA Screen of Basal-like TNBCsBasal-like Cell Lines Rely on BPLER Dependency Genes
More Than Other Breast Cancers
To evaluate whether the screen captured intrinsic vulnerabilities
of specific tumor subtypes, we assessed the dependence of 17
human breast cancer cell lines (Neve et al., 2006) (seven basal-A
[basal-like], six luminal, three basal-B [mesenchymal], and one
unclassified [from a squamous carcinoma]) by transfection with
siRNA pools targeting 15 BPLER dependency genes implicated
in the proteasome (PSMA1, PSMA2, and PSMB4, all of which
significantly affect proteasome activity; Figure S4A), spindle
checkpoint (NDC80, CASC5, RAN, BUB1, and NUF2), meta-
bolism (DHRS13, PFKL, and GAPDH), molecular transport
(DDX19B and RFT1), RNA splicing (PRPF8), and survival
(MCL1) (Figure 4A). Cells were considered sensitive to knock-
down of specific genes if viability declined to %50% of control
cells after 72 hr. These breast cancer cell lines differed greatly
in their requirements for individual BPLER dependency genes.
However, basal-like cell lines sharedmore BPLER dependencies
than non-basal-like cell lines. In fact, all seven basal-like cell lines186 Cancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc.were dependent on at least 5 of these 15 genes, whereas only 2
of 6 luminal cell lines and none of the basal-B cell lines shared
five dependencies. HCC70 and MB468 dependencies most
closely resembled BPLER. Basal-like cell lines were more similar
to BPLER and to each other than to non-basal-like cell lines (Fig-
ure 4B). Of note, dependency on MCL-1 was a feature of 6 of 7
basal-like cell lines, and 5 of 7 basal-like cell lines were suscep-
tible to knockdown of at least two proteasome component
genes, whereas non-basal-like cell lines were usually resistant.
Thus, although many BPLER dependencies were not shared
with basal-like TNBC, most basal-like TNBCs shared depen-
dency on the proteasome and MCL-1.
BPLER Dependency Gene Expression Correlates with
Poor Prognosis, Specifically in Human Breast Cancer
We next examined whether expression of BPLER dependency
genes was associated with tumor subtype in breast cancer pa-
tients using the NKI mRNA expression profiles of 295 primary
breast cancers, classified as basal-like, HER2+, luminal A,
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Figure 4. BPLER Dependency Genes Are Associated with a Basal-like TNBC Phenotype and Are Upregulated in Poor Prognosis Breast
Tumors
(A) Evaluation of a subset of BPLER screening hits by knockdown in 17 human breast cancer cell lines of different subtypes. Each cell line was transfected with a
control siRNA or specific siRNA pools against the indicated genes. Cell viability was assessed after 72 hr. Black boxes indicate viability%50% of control siRNA-
transfected cells. Color codes for breast cancer cell lines: Luminal (blue), Basal-A (red), Basal-B (green); HCC1806 and HMLER are squamous (purple).
Comparable transfection efficiency (>80%) for each cell line was verified using a fluorescent siRNA and showing <50% viability after transfection with PLK1
siRNA.
(B) Network showing the degree of similarity in dependencies between BPLER and the other breast cancer cell lines, evaluated and color coded as in (A). Cell lines
with no or only one shared dependency are not included. Edge thickness increases with shared dependencies (max = 10) and the most similar cell are closest.
(C) Patients in the NKI database of 295 human breast primary cancers were analyzed by single sample gene set enrichment analysis (GSEA) for expression of
BPLER dependency genes and the subset of highly selective genes. A Z score for expression of the signature genes was calculated for each sample. The scores
are shown as bean plots to compare the distributions in the tumor subtypes (Basal, basal-like; Lum, luminal; NL, normal-like). Each bean consists of a green line
for each sample with the overall distribution for the subtype represented as a gray density shape and a black line indicating the median Z score. * see text for
p values.
(D–F) Breast tumors from the NKI data set and lung and colon tumors from two independent data sets were divided into two groups based on their expression of
the dependency genes (high, red; low, blue). Kaplan-Meier curves show survival in breast (D), lung (E), and colon (F) cancer patients with higher tumor expression
of all dependency genes (top) or the highly selective subset (bottom).
See also Figure S4 and Table S5.
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siRNA Screen of Basal-like TNBCsluminal B, or normal-like (van de Vijver et al., 2002). The depen-
dency genes were significantly overexpressed in basal-like and
luminal B tumors (which histologically are intermediate between
basal-like and luminal A), relative to other subtypes (p < 33 105
and 4 3 106, respectively, by Kolmogorov-Smirnov test) (Fig-
ure 4C). The same two subtypes also significantly overexpressed
the 23 validated highly selective genes (p < 3 3 106 and 4 3
105). To determine whether BPLER dependency gene expres-
sion correlates with poor prognosis in breast cancer, we divided
the NKI tumors into two groups based on expression of the 23
highly selective or 154 BPLER dependency genes. Patients
with high expression of the dependency genes had significantly
reduced survival and time tometastasis, whichweremore signif-
icant if the analysis was restricted to the highly selective hits (Fig-
ures 4D and S4B).
To validate these findings and determine whether the BPLER
dependency genes are specific for breast cancer, the effect of
BPLER dependency gene expression on survival andmetastasis
was assessed in seven additional human tumor data sets (three
breast, two colon, and two lung) comprising 1,296 human pri-
mary tumors (Figures 4E and 4F; Figure S4B–S4D; Table S5)
(Hou et al., 2010; Jorissen et al., 2009; Pawitan et al., 2005;
Schmidt et al., 2008; Smith et al., 2010; Wang et al., 2005). In
the three additional breast cancer cohorts, expression of the
most selective and complete dependency genes again signifi-
cantly correlated with poor survival and early metastasis.
However, there was no significant association with survival or
metastasis in colon or lung cancer. Thus, BPLER dependency
gene expression correlated with poor clinical outcome specif-
ically in breast cancer. The significant link to poor survival in
breast cancer persisted even if the analysis was performed
excluding all genes linked to proliferation (Figure S4E) (Venet
et al., 2011). High expression of proteasome-related hits or
MCL1 was also associated with poor prognosis in breast, but
not lung or colon, tumors (Figures S4F and S4G).
Many published breast cancer signatures are not significantly
better outcome predictors than random signatures of identical
size (Venet et al., 2011). We used the NKI data set to compare
the predictive value of the BPLER dependency genes with
1,000 randomly generated gene signatures of the same size (Fig-
ure S4H). The 154 BPLER dependency genes and the subset of
23 highly selective hits outperformed random gene signatures
(p < 0.01 and p < 0.0001, respectively). The superior predictive
power of these gene sets persisted after eliminating prolifera-
tion-related genes. Thus BPLER dependency genes are upregu-
lated in basal-like tumors and correlate with poor prognosis
selectively in breast cancer.
Proteasome Inhibitors Are Selectively Active against
Basal-like Cell Lines
Among BPLER dependencies, the proteasome stood out. More-
over, 5 of 7 basal-like cell lines were susceptible to PSMA1 and
PSMA2 knockdown. To investigate proteasome dependence,
viability of BPE (TERT-immortalized epithelial cells, Figure 1A)
and 24 breast cancer cell lines was measured 24 hr after treat-
ment with a low concentration (12.5 nM) of the proteasome inhib-
itor bortezomib. Although inhibition of proteasome activity in
basal-like versus non-basal-like cell lines was comparable (Fig-
ure S5A), bortezomib was highly lethal for BPLER and basal-188 Cancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc.like cell lines compared to luminal and mesenchymal cell lines
(p < 0.001 and p < 0.006, respectively; Figures 5A and S5B).
Basal-like cell lines were more sensitive to bortezomib across
a broad range of drug concentrations (Figure 5B). Moreover, bor-
tezomib was only slightly cytotoxic to BPE. The in vitro LD50 of
bortezomib for sensitive basal-like cell lines was5–10 nM. Car-
filzomib (a second-generation proteasome inhibitor drug) also
selectively killed basal-like cell lines but was active in vitro at
60-fold lower concentrations than bortezomib (Figures S5C
and S5D; data not shown).
RAS activation and inactivation of TP53 and RB1 function are
frequent in basal-like tumors. However, stable transduction of
proteasome-resistant luminal MCF7 cells with active HRAS or
dominant-negative TP53 or with a small hairpin RNA against
RB1 did not modify their response to bortezomib, suggesting
that these functional alterations were not sufficient to confer pro-
teasome dependence (Figure S5E).
Basal-like T-ICs Are Sensitive to Proteasome Inhibition
A goal of current cancer therapeutics research is to eliminate
T-ICs. To examine whether proteasome inhibitors might be
active not only against the bulk of cells but also against the
T-ICs within basal-like cell lines, we examined the effect of
short-term (24 hr), low-dose (12.5 nM) bortezomib exposure on
in vitro colony and sphere formation. Basal-like cell lines that
form colonies when plated at clonal density (HCC1937,
HCC1143, and HCC1954) lost the ability to form colonies after
bortezomib treatment, whereas resistant clones emerged after
paclitaxel treatment (Figure 5C and S5F). In contrast, although
exposure to bortezomib or paclitaxel reduced colony formation
by luminal MCF7 and mesenchymal-like MB231 cells, resistant
clones invariably emerged. Likewise, among breast cancer cell
lines that form spheres under nonadherent conditions, bortezo-
mib, but not paclitaxel, eliminated sphere-forming cells in basal-
like cell lines (Figure 5D). Bortezomib also strongly inhibited
sphere formation by 2 of 3 mesenchymal cell lines (MB231 and
BT549, but not MB436), even though these cell lines as a whole
were resistant to bortezomib, but not by two luminal cell lines
(MCF7 and BT474). Treatment with bortezomib for 24 hr also
decreased viability of mouse 4T1E, a highly malignant basal-
like triple-negative 4T1 subclone, which is enriched for T-IC
(Figures S5G–S5J). The 40% of 4T1-E cells that survived bor-
tezomib were unable to form colonies in vitro or initiate tumors in
syngeneic mice (Figure 5E). Thus, proteasome inhibitors are
active against T-ICs within basal-like cell lines.
Proteasome Inhibition Suppresses TNBCOutgrowth and
Metastasis In Vivo
To investigate whether bortezomib is effective in vivo, protea-
some activity in BPLER tumors in nude mice was measured
18 hr after a single injection of 0.8 mg/kg bortezomib given intra-
tumorally (i.t.), intraperitoneally (i.p.), or intravenously (i.v.) (Fig-
ure 6A). Nearly complete proteasome inhibition was achieved
via i.t. injection, whereas i.p. and i.v. routes were ineffective, sug-
gesting that bortezomib does not penetrate efficiently into
tumors. However, increasing the i.v. dose to 1.6 mg/kg, the
maximally tolerated dose, inhibited proteasome activity in the
tumor. BPLER tumor outgrowth was evaluated by following
tumor volume and measuring tumor weight at sacrifice in mice
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Figure 5. Basal-like TNBC Cells and Their T-IC Are Selectively Sensitive to Proteasome Inhibition
(A) Viability of 22 breast cancer cell lines 24 hr after treatment with bortezomib (12.5 nM) relative to vehicle control assessed by CellTiter-Glo. The top and the
bottom of each box represent the 75th and 25th percentile of cell viability, respectively. Upper and lower whiskers represent maximum and minimum cell viability,
respectively. The black horizontal band in each box corresponds tomedian viability. * p < 0.005; ** p < 0.001. Data for individual cell lines are shown in Figure S5B.
(B) Dose-response curve of breast cancer cell lines treated with bortezomib for 24 hr.
(C and D) Colony (C) and sphere formation (D) assays of cell lines treated with bortezomib (12.5 nM) or paclitaxel (100 nM) for 18 hr and cultured for 2 weeks in
drug-free medium. Colonies were allowed to overgrow to enhance detection of slow-growing colonies.
(E) Colony formation (left) and tumor-initiation (right) of viablemouse 4T1E cells after treatment with bortezomib (12.5 nM) for 18 hr ex vivo (at which point40%of
cells are viable), followed by culture for 2 weeks in drug-free medium (colony assay, left) or mammary fat pad injection in BALB/c mice (tumor initiation, right).
Data in (B), (D), and (E) show mean ± SD and are representative of at least three independent experiments.
See also Figure S5.
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siRNA Screen of Basal-like TNBCstreated every 3 days i.t. (0.8 mg/kg) or weekly i.v. (0.5 or
1.6mg/kg) after subcutaneous tumors became palpable (Figures
6B, 6C, S6A, and S6B). As expected, treatment with low dose i.v.
bortezomibwas ineffective. Compared to control mice, tumors in
bortezomib-treated mice were 85% (i.t.) and 59% (high dose i.v.)
smaller (p < 0.01 and p < 0.02, respectively) and weighed 92%
(i.t.) and 63% (high dose i.v.) less (p < 0.001 and p < 0.006,respectively). Bortezomib induced CASP3 and PARP1 cleavage
in BPLER tumors, when assessed by immunohistochemistry
(Figure 6D) and immunoblot (Figure 6E), suggesting that bortezo-
mib impeded tumor outgrowth by inducing apoptosis. Likewise,
weekly i.v. bortezomib (1.6 mg/kg) inhibited further growth of
palpable basal-like MB468 and HCC1187 tumors (Figures 6F
and 6G; Figures S6C–S6E) but not luminal MCF7-HRASV12 andCancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc. 189
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Figure 6. Proteasome Inhibition Suppresses TNBC Growth In Vivo
(A) Proteasome activity in protein lysates from individual subcutaneous BPLER tumors (three mice/group) 18 hr after intratumoral (i.t.), intraperitoneal (i.p), or
intravenous (i.v.) treatment with bortezomib at the indicated dose, as determined by Proteasome-Glo assay, normalized by tissue weight. Proteasome activity in
BPLER treated with 12.5 nM bortezomib in vitro is shown as control (C). The mean ± SD of three replicates is shown. Red bars indicate significant proteasome
inhibition (p < 0.05).
(B and C) Tumor weight in BPLER tumor-bearing mice (five mice/group) after treatment with bortezomib or DMSO.
(D) Immunohistochemistry of BPLER tumors treated i.t. with 0.8 mg/kg bortezomib or DMSO every 3 days.
(legend continued on next page)
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siRNA Screen of Basal-like TNBCsAU565 tumors (Figures 6H, 6I, S6F, and S6G), mirroring the
in vitro sensitivity profile of these cell lines.
Xenografts in immunodeficientmicemay not accurately reflect
what happens in tumor-bearing immunocompetent hosts. We
therefore also assessed the effect of bortezomib in syngeneic
murine TNBC tumor models. Tumors formed in BALB/c mice
orthotopically implanted with 4T1E cells were inhibited by i.v.
bortezomib, even at the lower dose of 0.8 mg/kg (Figures 6J
and S6H). We also assessed the effect of low- and high-dose
i.v. bortezomib on lung metastases that form when 4T1E cells
are injected i.v. At both doses, bortezomib completely inhibited
the formation of lung metastases, assessed by counting tumor
nodules after intratracheal injection of India ink (Figures 6K and
6L). Tp53+/ BALB/c mice spontaneously develop breast can-
cers, many of which resemble human basal-like TNBCs histolog-
ically (Yan et al., 2010). Tumor fragments from spontaneous
basal-like TNBCs were implanted into the mammary fat pad of
BALB/c recipients, half of whom were treated weekly with i.v.
bortezomib. Tumors in bortezomib-treated mice (1.6 mg/kg
i.v.) were 90% smaller and weighed 80% less on average
than in DMSO-treated mice (p < 33 106 and p < 0.001, respec-
tively, Figures 6M, S6I, and S6J). Thus, proteasome inhibition
was effective in multiple models of human and mouse basal-
like breast cancer in vivo.
Proteasome Inhibition Induces Apoptosis in BPLER by
Promoting NOXA Accumulation
Although low-dose bortezomib inhibited proteasome activity to a
similar extent (Figure S7A), BPLER cells died, but HMLER were
largely resistant (Figures S5C). Both BPLER and HMLER were
equally sensitive to doxorubicin (Figure S7B). To begin to under-
stand the molecular basis of proteasome addiction in basal-like
cells, we first examined how bortezomib-treated BPLER cells
died. After treatment with bortezomib for 16 hr, BPLER selec-
tively underwent caspase-mediated apoptosis that involved
mitochondrial depolarization and outer membrane permeabiliza-
tion, CASP3 activation and PARP cleavage (Figures 7A, 7B, S7C,
and S7D). Apoptosis was inhibited by the pan-caspase inhibitor
zVAD-fmk (Figure S7C) and by knocking downBAX andBAK, the
bcl-2 family members that trigger the mitochondrial apoptotic
pathway (Figure 7C). However, BPLER cell numbers were not
completely restored by inhibiting apoptosis because bortezomib
also inhibited cell proliferation (data not shown).
A targeted RNAi screen of 22 factors implicated in regulating
apoptosis and the cytotoxic effect of bortezomib identified the
BH3-only protein NOXA as an essential and specific mediator
of the bortezomib response in BPLER (Figure 7D). Silencing(E) Immunoblot of protein lysates from BPLER tumors 18 hr after a single i.v. dos
individual mouse tumor.
(F–J) Tumor weight in HCC1187 (F), MB468 (G), MCF7-HRASV12 (H), AU565 (I), a
DMSO at the indicated dose, whichwas begun when tumors became palpable (50
subcutaneously. 4T1E cells were injected in the mammary fat pad.
(K and L) Representative India-ink-stained whole lungs from BALB/c mice (four m
injection, mice were treated with i.v. bortezomib (0.8 mg/kg q3d or 1.6 mg/kg q7d
and the mean ± SD of metastatic nodules determined by counting is shown in (L
(M) Tumorweight after weekly i.v. bortezomib (1.6mg/kg) or DMSO inmice implan
arising tumor (five mice/group). Treatment was started 2 days after implantation.
time of sacrifice. *p < 0.05.
See also Figure S6.PMAIP1 (the gene encoding for NOXA) rescued BPLER cells
from bortezomib comparably to zVAD-fmk. In contrast,
knockdown of BCL2L1 orMCL1, but not BCL2, augmented bor-
tezomib-induced death. This screen suggested that other mech-
anisms previously linked to proteasome inhibition, such as p53
activation, NF-kB inhibition, or death receptor signaling, were
not relevant in bortezomib-treated BPLER. Additional experi-
ments also showed that bortezomib-induced cell death in
BPLERwas notmediated by changes in NF-kB signaling, cellular
differentiation, or autophagy (Figures S7E–S7G). Although borte-
zomib caused some ER stress, treatment with any of three ER
stressors for 24 hr did not induce BPLER apoptosis (Figures
S7H and S7I). Bortezomib-induced death also was not blocked
by cotreatment with antioxidants or ERK, MEK, p38, or JNK
chemical inhibitors, suggesting that these pathways were not
critical (Figure S7J).
NOXA is degraded by ubiquitylation and the proteasome
(Gomez-Bougie et al., 2007). NOXA, but not other BH3-only pro-
teins, increased dramatically in BPLER cells treated with borte-
zomib in the presence of zVAD-fmk (Figure S7K). NOXA protein
also increased in vivo in bortezomib-treated BPLER xenografts
(Figure 6E). NOXA expression was regulated both transcription-
ally and posttranscriptionally, because NOXA protein increased
at a low bortezomib concentration that did not alter PMAIP1
mRNA (Figures S7L and S7M). To determine whether other pro-
apoptotic BH3-only proteins contribute to bortezomib-mediated
BPLER death, we examined the effect of their knockdown on
BPLER viability after bortezomib treatment (Figure 7E). Only
knockdown of PMAIP1 rescued BPLER from bortezomib. Taken
together, these data suggest that NOXA mediates BPLER death
from bortezomib.
NOXA Accumulation and MCL-1 Dependence Underlie
Basal-like Breast Cancer Cell Line Sensitivity to
Proteasome Inhibition
We next examined whether NOXA was responsible for protea-
some dependency in basal-like cells more generally. Treatment
with bortezomib for 24 hr activated PARP and CASP3 cleavage
in basal-like MB468, HCC1187, and HCC70 cells, but not in non-
basal-like MCF7, BT474, and HCC1428 cells (Figure 8A). Both
basal-like and mesenchymal TNBC cell lines expressed 5-to
25-fold more PMAIP1 mRNA than immortalized normal breast
epithelial cells or most luminal breast cancer cell lines (Fig-
ure S8A). Treatment with bortezomib increased NOXA protein
in all but one TNBC cell line but had less of an effect on NOXA
levels in immortalized breast epithelial cells and luminal cell lines
(Figure 8B). Thus, the proteasome blocked accumulation ofe of bortezomib (1.6 mg/kg) or DMSO. Each lane represents a sample from an
nd 4T1E (J) tumor-bearing mice after treatment with weekly i.v. bortezomib or
–100mm3). HCC1187,MB468,MCF7-HRASV12, and AU565 cells were injected
ice/group) after i.v. injection of 23 105 4T1E cells. Beginning 2 days after 4T1E
) or DMSO. The most prominent metastatic nodules are indicated by arrows (K),
).
ted in themammary fat padwith tumor fragments from the same spontaneously
Box-and-whisker plots (B, C, F, G, H–J, and M) show median tumor weight at
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Figure 7. Proteasome Inhibition Selectively Induces Apoptosis in BPLER by Promoting NOXA Accumulation
(A) Immunoblot of cells treated for 16 hr with bortezomib (12.5 nM). Each sample was assessed in duplicate independent samples.
(B)Mitochondrial depolarization, assessed by the percentage of DilC1(5)low BPLER andHMLER cells after treatment with 12.5 nMbortezomib, was determined by
flow cytometry.
(C–E) Viability of BPLER cells transfected with the indicated siRNAs and then treated 24 hr later with 12.5 nM bortezomib or DMSO for 24 hr. zVAD-fmk was used
as control. Data for each siRNA were normalized to viability of DMSO-treated cells. Data in (B)–(E) indicate mean ± SD. * p < 0.05.
See also Figure S7.
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siRNA Screen of Basal-like TNBCsNOXA protein in most TNBC cell lines. NOXA appeared to be
especially lethal in basal-like cell lines, because NOXA overex-
pression induced cell death in two basal-like cell lines (MB468
and HCC1187), but not in two non-basal-like cell lines (MB436
and HCC1806) (Figure S8B). Conversely, PMAIP1 silencing in-
hibited bortezomib-induced death in basal-like MB468 and
HCC1187 (Figure S8C).
NOXA exerts its proapoptotic effect by binding to MCL-1 and
BCL2A1 (Deng et al., 2007). MCL-1, a hit in the BPLER screen,
was also a dependency factor for 6 of 7 additional basal-like
cell lines (Figure 4A). The amount of NOXA bound to MCL-1
increased with bortezomib treatment in basal-like MB468 and
HCC1187 (Figure S8D). Moreover, MCL1 knockdown was suffi-
cient to induce PARP and CASP3 cleavage in basal-like MB468
and HCC1187, but not in non-basal-like MB231 andMB436 (Fig-
ure 8C). Together, these data suggest that one mechanism by
which proteasome inhibition kills basal-like cell lines is by accu-
mulation of NOXA, which in turn antagonizes MCL-1, which192 Cancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc.these cells depend on for survival. In fact, MCL-1 dependency,
assessed by cell viability after MCL-1 knockdown, strongly
correlated with bortezomib sensitivity in TNBC cell lines (r =
0.93, p < 0.0005; Figure 8D). Of note, BT20, the only bortezo-
mib-resistant basal-like cell line, weakly expressed NOXA
protein and was MCL-1 independent (Figures 4A and 8B).
Steady-state levels of MCL-1 were similar in proteasome-sensi-
tive and insensitive breast cancer cell lines of diverse types (Fig-
ure S8E); moreover, in response to bortezomib, MCL-1 was
slightly increased in both sensitive and resistant cell lines in the
presence of zVAD (Figure S8F). Thus, bortezomib sensitivity
of basal-like cell lines was not due to decreased MCL-1
expression.
DISCUSSION
We used unbiased siRNA screening to uncover the functional
dependencies of a basal-like TNBC cell line enriched for T-ICs
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Figure 8. Bortezomib Sensitivity of Basal-like TNBC Is Linked to NOXA Accumulation and MCL-1 Dependency
(A and B) Immunoblot of breast cancer cell lysates treated or not with 12.5 nM bortezomib for 24 hr.
(C) Immunoblot of breast cancer cells 24 hr after transfection with an siRNA against MCL1 or a nontargeting siRNA (control).
(D) Scatter plot showing cell viability 72 hr afterMCL1 knockdown (x axis) and 24 hr after 12.5 nM bortezomib treatment (y axis) in TNBC cell lines and BPE cells.
Color scheme in (A)–(D) as indicated in (B). All data are representative of at least three independent experiments. *p < 0.05.
See also Figure S8.
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siRNA Screen of Basal-like TNBCsas a starting point for identifying candidate drug targets of basal-
like TNBCs and potentially for the subpopulation of T-ICs within
them. MCL-1 and proteasome dependency were unanticipated
common features of most basal-like TNBC cell lines that were
only occasionally shared by other breast cancers. Treatment
with a clinical proteasome inhibitor bortezomib not only inhibited
basal-like tumor outgrowth but also inhibited metastasis. Impor-
tantly, bortezomib was effective against T-ICs within basal-like
TNBC cell lines—it inhibited in vitro surrogate assays of T-IC
function as well as tumor initiation. This is an important finding
because there are currently no effective therapies targeted at
eliminating T-ICs, which are generally relatively drug resistant
and widely believed to be responsible for relapse andmetastasis
(Valent et al., 2012).
All cells rely on the proteasome for protein homeostasis.
Therefore, it might seem surprising that some cells are more
dependent on this housekeeping function than others. For multi-
ple myeloma cells, which are factories for producing andsecreting immunoglobulin protein, selective proteasome depen-
dence seems to make sense, because interfering with the ability
of cells to remove unfolded proteins can lead to ER stress and
apoptosis. However, why other types of cancer cells are sensi-
tive to proteasome inhibition is not well understood. The effects
of proteasome inhibition on cancer cells can lead to cell death by
multiple mechanisms (Eldridge and O’Brien, 2010). Here, we
found that proteasome dependency in BPLER and basal-like
TNBCs is linked to MCL-1 dependency and mediated by
NOXA. The proteasome degrades NOXA (Ohshima-Hosoyama
et al., 2011). The link to MCL-1 is not surprising because MCL-
1 is an antiapoptotic Bcl-2 family member antagonized by
NOXA. A link among MCL-1, NOXA, and proteasome sensitivity
has already been shown in some hematopoietic malignancies
(Dasmahapatra et al., 2012), but not in TNBC. Moreover, MCL-
1 expression is linked to poor prognosis in TNBCs (Ding et al.,
2007; Placzek et al., 2010). However, although NOXA is also
highly upregulated by proteasome inhibition in mesenchymalCancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc. 193
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siRNA Screen of Basal-like TNBCsTNBC lines, they are resistant to bortezomib and are not depen-
dent on MCL-1. The reason for this difference is unclear. To take
advantage of proteasome andMCL-1 dependency in developing
targeted therapies for TNBCs, it will be important to understand
better why basal-like TNBC are especially vulnerable to MCL-1
inhibition and why mesenchymal TNBCs are able to survive it.
The tight linkwe foundbetweenMCL-1 and proteasome sensi-
tivity (Figure 8D) in TNBC could be useful for identifying tumors
that will respond to proteasome inhibitor therapy. Inhibiting
MCL-1, using aBH3-mimetic, such asGX15-070 (Dasmahapatra
et al., 2012), or lowering its expression via inhibition of cyclin-
dependent kinases or glucose metabolism (Pradelli et al., 2010)
might synergize with proteasome inhibition in basal-like TNBCs.
Proteasome inhibitors failed to show clinical benefit in small
unstratified breast cancer trials (Awada et al., 2008; Engel
et al., 2007; Schmidt et al., 2008). Based on our findings, this is
not surprising, because proteasome addiction is a feature of
only a subset of TNBCs. TNBCs comprise only 15% of all
breast cancers and only about half of these are basal-like (Leh-
mann et al., 2011). Poor penetration into the tumor is a well-
known limitation of bortezomib that might partly explain its lack
of efficacy in solid tumors. In fact, the maximally tolerated borte-
zomib dose in mice was needed to achieve proteasome inhibi-
tion of xenografted tumors. At least 14 novel proteasome inhib-
itors are in advanced clinical development, and one, carfilzomib,
has been approved for multiple myeloma (Cohen and Tcherpa-
kov, 2010). Proteasome inhibitors with improved pharmacoki-
netics and pharmacodynamics should further improve re-
sponses. It is worth evaluating these drugs in basal-like TNBCs.
Is the BPLER cell line a reasonable model for basal-like
TNBCs? No individual cell line can hope to recapitulate the ge-
netic heterogeneity of these tumors, and the oncogenes used
for transformation of BPLER are not representative of TNBCmu-
tations. Nonetheless, we chose BPLER in combination with
HMLER for our screen because these two cell lines are remark-
ably epigenetically stable in chemically defined media in vitro
with very distinct phenotypes, while harboring the same set of
transforming oncogenes. BPLER have the bipotent epithelial
progenitor phenotype of many basal-like TNBCs and form tu-
mors that resemble basal-like TNBCs histologically and by
gene expression. HMLER give rise to squamous tumors, a rare
form of breast cancer. Thus, these two genetically well-defined,
virtually isogenic cell lines offered an opportunity to pinpoint
selective dependencies associated with a basal-like phenotype.
Although BPLER may only partially represent basal-like TNBCs,
the BPLER screen identified candidate genes that might be
essential for breast tumor cells locked in a progenitor-like state.
BPLER are also attractive because they are highly enriched for
T-IC, which normally represent a minor subpopulation of breast
cancer cell lines and are difficult to study in vitro. In fact the only
other human TNBC cell line enriched for T-IC is derived from
HMLER by stable knockdown of E-cadherin (HMLER-shEcad)
(Gupta et al., 2009). However, HMLER-shEcad cells uniformly
form mesenchymal (not basal-like) tumors in immunodeficient
mice. Thus, the BPLER and HMLER-shEcad T-ICs are likely
quite distinct. These results suggest that even TNBC T-ICs are
heterogeneous.
Although 18,000 genes were screened using pools of four
siRNAs/genes, certain BPLER dependencies might have been194 Cancer Cell 24, 182–196, August 12, 2013 ª2013 Elsevier Inc.missed, because some poolsmay have failed to induce sufficient
gene silencing. Moreover, elimination of genes whose knock-
downwas lethal to both BPLER andHMLERmay have discarded
possible drug targets that might be effective for a broader range
of breast cancers.
Our screen identified 154 BPLER dependency genes whose
expression was linked to poor prognosis specifically in breast
cancer, but not in colon or lung cancer. Expression of the stron-
gest hits, only 23 genes, was just as predictive as the longer list, if
not better. About 20%of these hits promote cell proliferation, but
the proliferation-related genes did not explain the prognostic
value of the gene list, since removing them did not seriously alter
their ability to identify poor prognosis tumors. Combining the
BPLER dependency gene list with lists of dependencies of other
TNBCs, that need to be experimentally identified, should provide
even better prognostic gene signatures that could guide patient
therapy.
The BPLER dependency gene list, which is of a manageable
size, may point the way to other potential TNBC drug targets.
For example, the dependency genes include glycolytic enzyme
genes. In preliminary studies, we found that BPLER are
selectively sensitive to glycolysis inhibition. In fact, a recent
study identified glycolysis as a selective TNBC dependency
(McCleland et al., 2012). A recent chemical screen in HMLER-
shEcad identified the potassium ionophore salinomycin as a
candidate drug (Gupta et al., 2009). Three BPLER dependency
genes are potassium-sodium exchange transporters, suggest-
ing that specific ion transport inhibition may also be effective
against basal-like TNBCs. Drugs that inhibit mitosis, like pacli-
taxel, form the basis of current TNBC treatment. The BPLER
dependency list includes multiple genes involved in mitosis. It
is, however, uncertain why BPLER is selectively sensitive to in-
hibiting mitosis compared to other cancer cells like HMLER,
which proliferate at a similar rate.EXPERIMENTAL PROCEDURES
RNAi Screen
Screening was performed at the Harvard ICCB-L Screening Facility (http://
iccb.med.harvard.edu) using the Human siGenome siRNA Library (Dharma-
con). Library plates with >50% of siRNA pools targeting deprecated genes
(i.e., putative transcripts no longer supported by transcript evidence) were
excluded. A total of 17,378 siRNA pools, each targeting a different gene,
were evaluated. Individual siRNAs in the library have not been validated.
Thus, the percentage of siRNA pools that effectively induce gene silencing,
or the extent and duration of protein knockdown, is unknown. The manufac-
turer estimates that most siRNA pools contain at least one effective siRNA.
Procedures were optimized and validated for high-throughput screening under
ICCB-L guidance. Screening conditions were identical for BPLER and HMLER
cells. For each cell line, each siRNA or pool of siRNAs was transfected in trip-
licate wells. Eachmicroplate included eight negative and eight positive internal
controls to monitor experimental conditions across the screen. Only micro-
plates with a Z’ factor >0.5 were analyzed (covering 98.7% of the siRNA li-
brary). Cells were dispensed with WellMate rapid plate dispensers and
Teflon-coated manifolds (Matrix). siRNAs libraries were transferred into 384-
well assay plates using liquid handling robots (Velocity 11 Bravo). siRNAs
were reverse-transfected with Dharmafect #1 (Dharmacon) in WIT medium us-
ing a final concentration of 50 nM in 384-well white/clear microplates (Corning
Cat. # 3707). Fresh medium was added after 24 hr, and cell viability was as-
sessed by CellTiter-Glo (Promega) 3 days after transfection using an Envision
high-throughput plate reader (PerkinElmer). A detailed description of the pro-
tocol is available upon request.
Cancer Cell
siRNA Screen of Basal-like TNBCsExpression Analysis
Expression arrays and clinical data used in the study are listed in Table S5.
Normalized expression tables were downloaded from the NCBI Gene Expres-
sion Omnibus (http://www.ncbi.nlm.nih.gov/geo) using the R package
GEOquery. The associated metadata were retrieved using GEOmetaDB.
Clinical and expression data for the NKI data set were accessed using
the R package breastCancerNKI. http://compbio.sph.harvard.edu/hidelab/
pathprint was used to map probes to Entrez Gene IDs, merging multiple
probes by their mean expression levels using systematically updated annota-
tions obtained from AILUN. Gene expression of BPLER tumor explants was
analyzed using Affymetrix arrays and Affymetrix GENECHIP software normal-
ized using Mas5 in R.
Principal Component Analysis
Human breast tumor array data were obtained from two previous studies on
Agilent and Affymetrix arrays (Richardson data set [47 cases; Richardson
et al., 2006] and UNC data set [337 cases; Prat et al., 2010]). Differentially ex-
pressed genes across the tumor data sets were identified using the R package
Linear Models for Microarray Data (LIMMA). Array data were rank normalized
using genes common across the tumor and BPLER explant arrays. Principal
component analysis was based on the set of genes that differentiate the tumor
data sets.
Pathway Enrichment Analysis and Network Visualization
A p value for the overrepresentation of a suite of canonical pathways (KEGG,
Wikipathways, and Reactome) in the 154 gene signature was obtained using
the hypergeometric distribution. A visualization of the interactions between
the genes in the top enriched pathways was rendered using the Genemania
plugin within Cytoscape (Killcoyne et al., 2009). Eighty-seven genes formed
a single interacting network. Genes that participate in the major functional cat-
egories, but are not annotated to have direct protein interactions, were added
to this network to produce a core functional-interaction module. Similarities in
dependencies between BPLER and other breast cancer cell lines were visual-
ized using the Prefuse force-directed network plugin within Cytoscape.
Code Availability
The R code used to produce bioinformatic results and figures is available as
Sweave files upon request.
In Vivo Experiments
All animal procedures were performed with Harvard Medical School and Bos-
ton Children’s Hospital ACUC approval. See also the Supplemental Experi-
mental Procedures.
Studies Involving Human Subjects
Informed consent was not required.
ACCESSION NUMBERS
ThemRNAmicroarray data fromBPLER tumor explants in Figures 1G and S1G
were deposited into the GEO database (GSE48444).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
eight figures, and five tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2013.07.008.
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